Chiang Valerie, Leung Agnes S Y, Au Elaine Y L, Ho Marco H K, Lee Tak Hong, Wu Adrian Y Y, Wong Gary W K, Li Philip H
Division of Clinical Immunology, Department of Pathology, Queen Mary Hospital, Hong Kong, China.
Department of Paediatrics, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China.
Front Allergy. 2021 Jul 14;2:690837. doi: 10.3389/falgy.2021.690837. eCollection 2021.
Mass coronavirus disease 2019 (COVID-19) vaccination to achieve herd immunity is an effective means to mitigate the current COVID-19 pandemic. Reports of COVID-19 vaccine-associated allergic reactions and lack of clear local guidance are contributing factors leading to a low vaccine acceptance rate in the community. A task force of experts from the Hong Kong Institute of Allergy (HKIA) has been formed to address current needs. To formulate a set of consensus statements (CS) on COVID-19 vaccine allergy safety (VAS) in Hong Kong. A nominated task force of experts managing patients with drug and vaccine allergies in Hong Kong formulated the CS by the Delphi method. An agreement was defined as ≥80% consensus. A total of 11 statements met the criteria for consensus with good overall agreement among task force members, including seven statements on pre-vaccination recommendations and four statements on vaccination and post-vaccination guidance. Individuals with a history of suspected allergic reaction to prior COVID-19 vaccination should not receive further COVID-19 vaccination, and other groups at risk of COVID-19 vaccine-associated allergic reactions have been identified. The importance of pre-vaccination and post-vaccination assessment by frontline healthcare workers and evaluation by allergists are highlighted. The CS provides pragmatic and timely guidance for local frontline healthcare providers on decisions regarding COVID-19 VAS.
大规模接种2019冠状病毒病（COVID-19）疫苗以实现群体免疫是缓解当前COVID-19大流行的有效手段。关于COVID-19疫苗相关过敏反应的报告以及缺乏明确的本地指导是导致社区疫苗接种接受率较低的因素。香港过敏学会（HKIA）已成立一个专家特别工作组来满足当前需求，以制定一套关于香港COVID-19疫苗过敏安全性（VAS）的共识声明（CS）。香港一个负责管理药物和疫苗过敏患者的专家特别工作组通过德尔菲法制定了该CS。将达成≥80%的共识定义为达成协议。共有11项声明符合共识标准，工作组成员之间总体达成了良好的一致意见，其中包括7项关于接种前建议的声明以及4项关于接种和接种后指导的声明。有先前COVID-19疫苗接种疑似过敏反应史的个体不应再接种COVID-19疫苗，并且已确定了其他有COVID-19疫苗相关过敏反应风险的群体。强调了一线医护人员进行接种前和接种后评估以及过敏专科医生进行评估的重要性。该CS为本地一线医护人员在COVID-19 VAS相关决策方面提供了实用且及时的指导。
